Objective:To study the inhibitory effect of Fuzheng Yiliu Granule(扶正抑瘤颗粒,FYG) on hepatocellular cancer(HCC) and investigate the mechanism mediating its bioactivity.Methods:H22 tumor-bearing ICR mice were treated with FYG[3.6 g/(kg·d)]for 5 days.Tumor volume and tumor weight,percentages of CD3~+,CD4~+,CD8~+,and natural killer(NK) cells in peripheral blood,tumor apoptosis and serum levels of interleukin-2(IL-2),and tumor necrosis factor-α(TNF-α) were evaluated.FYG-containing serum was prepared from SD rats treated for 7 days[high dose 3.6 g/(kg·d);middle dose 1.8 g/(kg·d);low dose 0.9 g/(kg·d)].Cell cycle,cell viability,and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h.The levels of IL-2 and TNF-αin FYG-containing serum were also determined.Results:FYG produced a potent antitumor effect(P<0.01) and induced marked apoptosis of the tumor tissue(P<0.05).Mice treated with FYG had higher percentages of CD3~+ and CD4~+(P<0.05),and more NK cells(P<0.01) in the peripheral blood than those in the animals treated with normal saline.Mice receiving FYG had the highest serum levels of IL-2 and TNF-α(P<0.01).High-dose FYG-containing serum significantly decreased HepG2 cell viability,inhibited cell proliferation(P<0.05),and induced apoptosis(P<0.01).In addition,the levels of IL-2 and TNF-αof highdose -containing serum were higher than the blank serum(P<0.01).Conclusion:FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro. Objective: To study the inhibitory effect of Fuzheng Yiliu Granule on hepatocellular cancer (HCC) and investigate the mechanism mediating its bioactivity. Methods: H22 tumor-bearing ICR mice were treated with FYG [3.6 g / ( kg · d)] for 5 days. Volume and tumor weight, percentages of CD3 +, CD4 +, CD8 +, and natural killer (NK) cells in peripheral blood, tumor apoptosis and serum levels of interleukin-2 FQG-containing serum was prepared from SD rats treated for 7 days [high dose 3.6 g / (kg · d); middle dose 1.8 g / (IL-2), and tumor necrosis factor- kg · d); low dose 0.9 g / (kg · d)]. Cell cycle, cell viability, and apoptosis were evaluated after HepG2 cell line was cultured in FYG-containing serum for 48 h. The levels of IL-2 and TNF Results: FYG produced a potent antitumor effect (P <0.01) and induced marked apoptosis of the tumor tissue (P <0.05). Mice treated with FYG had higher percentages of CD3 ~ + and CD4 ~ + (P <0.05), a Mice receiving FYG had the highest serum levels of IL-2 and TNF-α (P <0.01). High-dose FYG- containing serum significantly decreased HepG2 cell viability, inhibited cell proliferation (P <0.05), and induced apoptosis (P <0.01) .In addition, the levels of IL-2 and TNF-αof high concentration -containing serum were higher than the blank serum ( P <0.01) .Conclusion: FYG could inhibit HCC growth by regulating immune function and inducing apoptosis of tumor cells in vivo and in vitro.